Poland· PL-100317691

Vokanamet

A metformin and canagliflozin product containing canagliflozinum + metformini hydrochloridum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 11 of our 19 countries.

ATC A10BD16

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedVokanametATCA10BD16REGISTER NO.PL-100317691PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Metformin and canagliflozin is registered in 11 of 19 countries.

Countries holding a registration under ATC A10BD16 (metformin and canagliflozin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Metformin and canagliflozin · ATC A10BD16

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Canagliflozinum + Metformini hydrochloridum
Manufacturer
Janssen-Cilag International N.V.
Country
Poland (PL)
ATC code
A10BD16
ATC class
Metformin and canagliflozin
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991142216
  • gtin
    05909991142223
  • gtin
    05909991142230

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for metformin and canagliflozin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Metformin and canagliflozin · interactions on record

2 records

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9c049791-227f-4c2a-8e1c-3cdaaf3ad2b5
GET /v1/drugs/9c049791-227f-4c2a-8e1c-3cdaaf3ad2b5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "150 mg + 850 mg",
  "packaging": "05909991142216 ¦ Rp ¦ EU/1/14/918/007 ¦ 92068\n20 tabl.\n05909991142223 ¦ Rp ¦ EU/1/14/918/008 ¦ 92069\n60 tabl.\n05909991142230 ¦ Rp ¦ EU/1/14/918/009 ¦ 92070\n180 tabl.",
  "substance": "Canagliflozinum 150 mg + Metformini hydrochloridum 850 mg",
  "common_name": "Canagliflozinum + Metformini hydrochloridum",
  "pl_product_id": "100317691",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about metformin and canagliflozin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.